secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001104659-23-088076
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee initiates dosing in Phase 1 trial of APG777 ahead of schedule for atopic dermatitis
--------------------------------------------------------------------------------

- First participants dosed in healthy-volunteer Phase 1 trial of APG777 ahead of initial timeline.
- APG777 is a novel half-life extended anti-IL-13 antibody for moderate-to-severe atopic dermatitis.
- Preclinical data suggest potential for dosing every two to three months, longer than existing therapies.
- Initial subcutaneous pharmacokinetic and safety data from healthy volunteers expected in mid-2024.
- Apogee plans to start a randomized Phase 2 trial in moderate-to-severe AD patients in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465923088076/0001104659-23-088076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465923088076/tm2322937d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer